血液系统恶性肿瘤患者接种第四剂及后续新冠疫苗剂次的免疫原性与安全性
这项在加拿大12个中心开展的前瞻性研究,于2021年8月至2023年1月纳入血液系统恶性肿瘤患者,采用干血斑法检测抗S抗体。372名参与者中,接种第四剂后257例(77.2%)抗S抗体阳性,接种第五剂后135例(90.6%)阳性;123例(34%)报告新冠感染,4例(1%)新冠相关住院,无新冠死亡。
要点
- 血液系统恶性肿瘤患者接种第四剂后77.2%抗S抗体阳性,第五剂后90.6%阳性。
- 第四剂前抗S阴性者中33.4%在第四剂后转阳;第五剂前阴性者中33.3%在第五剂后转阳。
- 372例中123例(34%)报告新冠感染,4例(1%)新冠相关住院,无新冠死亡。
核心结论
- 这项前瞻性队列研究显示,血液系统恶性肿瘤患者接种后续新冠疫苗剂次后体液免疫应答改善。
研究设计与样本
- 2021年8月至2023年1月在加拿大12个中心开展的前瞻性研究,纵向随访血液系统恶性肿瘤患者,按疫苗接种间隔提交手指采血干血斑卡片,采用高通量ELISA检测抗核衣壳(N)和抗刺突(S)蛋白血清抗体。
- 共获得790名独特患者的3071份样本;其中372名独特参与者有第四、五或六剂新冠疫苗后的1840份抗S结果样本纳入分析。
主要发现
- 372名参与者中333例提交了第四剂后干血斑样本,其中257例(77.2%)抗S抗体阳性。
- 198例有第四剂前后配对样本,其中59例(29.7%)第四剂前抗S抗体阴性,这59例中20例(33.4%)第四剂后抗S抗体转阳。
- 149例提交了第五剂后干血斑样本,其中135例(90.6%)抗S抗体阳性。
- 52例有第五剂前后配对样本,其中6例(8.7%)第五剂前抗S抗体阴性,这6例中2例(33.3%)第五剂后抗S抗体转阳。
- 372例中123例(34%)报告新冠感染,4例(1%)新冠相关住院,无报告新冠死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune response to COVID-19 vaccine is diminished in patients with hematologic malignancy. There is limited data regarding response to vaccine doses in these patients. PURPOSE: To quantify the humoral immune response engendered by 4th and subsequent doses of SARS-CoV-2 vaccination as measured by anti-Spike (anti-S) antibody levels, based on dried blood spot (DBS) testing, in patients with hematologic malignancies. Anti-S binds to the spike protein of the SARS-CoV-2 virus and is indicative of vaccine immunogenicity. METHODS: We conducted a prospective study of hematologic malignancies between August 2021 and January 2023 at 12 sites across Canada. Participants were followed longitudinally and submitted finger-prick DBS cards at set intervals associated with vaccination. Samples were processed via high throughput ELISA assay to detect serum antibodies against nucleocapsid (N) and spike (S) proteins. RESULTS: We obtained 3071 samples on 790 unique patients. Of these, 372 unique participants with 1840 samples had anti-S results available post-4th, 5th or 6th COVID-19 vaccine dose and were included for analysis. Three hundred thirty-three patients of the 372 participants submitted a DBS sample post 4th dose. Of these, 257 patients (77.2%) had a positive anti-S antibody. A total of 198 patients had paired samples pre- and post-dose 4, of which 59 (29.7%) had a negative anti-S antibody pre-dose 4. Of these, 20 (33.4%) developed positive anti-S antibody post-dose 4. One hundred forty-nine patients submitted a DBS sample post-dose 5. Of these, 135 patients (90.6%) had positive anti-S antibody. A total of 52 had paired samples pre- and post-dose 5. Six (8.7%) had a negative anti-S antibody pre-dose 5, of which two (33.3%) developed positive anti-S antibody post-dose 5. Of these 372 patients, 123 (34%) reported COVID-19 infection and 4 (1%) had a COVID-19 related hospitalization. There were no reported deaths from COVID-19. CONCLUSIONS: This prospective cohort study showed that humoral immune response improved with subsequent doses of COVID-19 vaccines.
引用
- Bhella S, Wilkin AM, Hueniken K, et al. COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies. Vaccine. 2024. PMID: 38944577. doi:10.1016/j.vaccine.2024.06.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。